Use of allogeneic tissue to treat infective valvular disease: Has everything been said?

J Thorac Cardiovasc Surg. 2017 Apr;153(4):824-828. doi: 10.1016/j.jtcvs.2016.09.071. Epub 2016 Oct 24.

Authors

Francesco Nappi¹, Cristiano Spadaccio², Christophe Acar³

Affiliations

¹ Cardiac Surgery Center, Cardiologique du Nord de Saint-Denis, Paris, France. Electronic address: francesconappi2@gmail.com.
² Department of Cardiothoracic Surgery, Golden Jubilee National Hospital, Glasgow, United Kingdom; Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, United Kingdom.
³ Department of Cardiovascular Surgery, Hôpital de la Salpétrière, Paris, France.

PMID: 27866779
DOI: 10.1016/j.jtcvs.2016.09.071

No abstract available

Publication types

Editorial
Video-Audio Media

MeSH terms

Allografts
Aortic Valve / physiopathology
Aortic Valve / surgery*
Bioprosthesis*
Clinical Decision-Making
Endocarditis / diagnosis
Endocarditis / physiopathology
Endocarditis / surgery*
Heart Valve Prosthesis Implantation / adverse effects
Heart Valve Prosthesis Implantation / instrumentation*
Heart Valve Prosthesis*
Humans
Mitral Valve / physiopathology
Mitral Valve / surgery*
Prosthesis Design
Recovery of Function
Risk Factors
Time Factors
Treatment Outcome